Login to Your Account



Actelion to Pay Asahi $91M Plus Under Arbitration Ruling

By Cormac Sheridan


Wednesday, December 30, 2009
Actelion Ltd.'s 2007 acquisition of CoTherix, Inc. has just gotten more expensive. The Allschwil, Switzerland-based firm is cutting about $80 million from its operating profit forecast for 2009, following a decision by an arbitration panel that it should pay $91 million, plus interest, to Asahi Kasei Pharma Corp. arising out of a termination of a drug development alliance involving CoTherix. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription